Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?
The Motley Fool · James Halley ·
Revolution Medicines isn't profitable, but it has a drug with blockbuster potential.
Read the full story at The Motley Fool · All coverage of this story